Emisphere Down 26% After Osteoarthritis Endpoints Miss
By Tom Wall
Monday, October 17, 2011
Shares in Emisphere Technologies Inc. dropped sharply following the Cedar Knolls, N.J.-based firm's announcement that it was informed by partner Novartis Pharma AG that the first interpretable results of a second Phase III study of oral calcitonin in patients with osteoarthritis of the knee missed co-primary and secondary endpoints.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.